UNCY

Unicycive Therapeutics Inc

Add to Watchlist

Advanced Chart

4.620

+0.14(3.125%)1D

Line

Candle

YTD

High

4.660

Open

4.430

VWAP

4.45

Vol

380.15K

Mkt Cap

81.60M

Low

4.280

Amount

1.69M

EV/EBITDA(TTM)

Total Shares

37.61M

34.87M

EV/OCF(TTM)

P/S(TTM)

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.600

+20%

-0.602

-76.85%

0.658

-231.67%

Estimates Revision

The market is revising Downward the revenue expectations for Unicycive Therapeutics, Inc. (UNCY) for FY2025, with the revenue forecasts being adjusted by -94.55% over the past three months. During the same period, the stock price has changed by 12.96%.

Revenue Estimates for FY2025

Revise Downward

-94.55%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-11.03%

In Past 3 Month

Stock Price

Go Up

+12.96%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is 38.25 USD with a low forecast of 21.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.620

Low

21.00

Averages

38.25

High

60.00

Current: 4.620

Low

21.00

Averages

38.25

High

60.00

H.C. Wainwright

NULL -> Buy

maintain

$9 -> $22

2025-10-29

Reason

H.C. Wainwright

Price Target

$9 -> $22

2025-10-29

maintain

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Unicycive Therapeutics to $22 from $9 and keeps a Buy rating on the shares. The believes the company's regulatory overhang has been revolved after its Type A meeting with the FDA. Unicycive plans to file a response to the complete response letter by year-end and expects a decision in the first half of 2026, the analyst tells investors in a research note.

Benchmark

Speculative Buy

maintain

$3 -> $21

2025-09-15

Reason

Benchmark

Price Target

$3 -> $21

2025-09-15

maintain

Speculative Buy

Reason

Benchmark raised the firm's price target on Unicycive Therapeutics to $21 from $3 and keeps a Speculative Buy rating on the shares, noting that the firm's new price target reflects a 1:10 reverse split and an updated discount rate after Unicycive said that it plans to complete a Type A meeting with the FDA to gain alignment on the best strategy to resolve the remaining issues outlined in the complete response letter for the oxylanthanum carbonate New Drug Application.

Lucid Capital

Elemer Piros

Buy

initiated

$12

2025-06-04

Reason

Lucid Capital

Elemer Piros

Price Target

$12

2025-06-04

initiated

Buy

Reason

H.C. Wainwright

Buy

initiated

2025-05-27

Reason

H.C. Wainwright

Price Target

2025-05-27

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Unicycive Therapeutics with a Buy rating and $9 price target. Unicycive is a clinical stage biotechnology company developing novel therapies for treating kidney diseases, the analyst tells investors in a research note. The firm expects a positive decision by the FDA for the company's leading clinical candidate, oxylanthanum carbonate, for lowering high phosphate levels or hyperphosphatemia in chronic kidney disease patients undergoing dialysis and expects management to launch the drug by the end of 2025.

Guggenheim

Vamil Divan

Strong Buy

Initiates

2025-04-21

Reason

Guggenheim

Vamil Divan

Price Target

2025-04-21

Initiates

Strong Buy

Reason

Guggenheim initiated coverage of Unicycive Therapeutics with a Buy rating and $6 price target.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$7.5

2025-04-11

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$7.5

2025-04-11

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Unicycive Therapeutics Inc (UNCY.O) is 2.73, compared to its 5-year average forward P/E of -0.51. For a more detailed relative valuation and DCF analysis to assess Unicycive Therapeutics Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.51

Current PE

2.73

Overvalued PE

6.64

Undervalued PE

-7.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6302.41

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

22733.71

Undervalued EV/EBITDA

-35338.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.62

Current PS

4.58

Overvalued PS

17.00

Undervalued PS

-7.77

Financials

Annual

Quarterly

FY2025Q2

N/A

Total Revenue

FY2025Q2

YoY :

-5.92%

-6.96M

Operating Profit

FY2025Q2

YoY :

-165.42%

-6.45M

Net Income after Tax

FY2025Q2

YoY :

-64.38%

-0.52

EPS - Diluted

FY2025Q2

YoY :

+32.92%

-8.43M

Free Cash Flow

FY2025Q2

N/A

Gross Profit Margin - %

FY2025Q2

N/A

FCF Margin - %

FY2025Q2

N/A

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

1.4M

Volume

Months

0-12

5.5M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

UNCY News & Events

Events Timeline

2025-10-30 (ET)

2025-10-30

07:19:23

Unicycive Therapeutics to Showcase New OLC Findings at ASN Kidney Week 2025

2025-10-28 (ET)

2025-10-28

07:09:19

Unicycive Offers Update on FDA Meeting and NDA Resubmission for OLC

2025-08-18 (ET)

2025-08-18

07:13:27

Unicycive Therapeutics Receives New U.S. Patent for UNI-494 in Chronic Kidney Disease Treatment

News

7.0

10-31Globenewswire

UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. Investigates Unicycive Therapeutics, Inc. for Long-Term Stockholders and Urges Investors to Reach Out to the Firm

9.0

10-30Newsfilter

Unicycive Therapeutics to Present New Data Highlighting the Promise of Oxylanthanum Carbonate for Hyperphosphatemia Treatment at the 2025 American Society of Nephrology Kidney Week Conference